View Article |
A narrative review on the effectiveness of Tocilizumab in reducing the mortality risk in COVID-19 patients
Nur Haifa Amani Binti Zulkiply1, Ravindran Muthukumarasamy2, Vignesh Ramachandran3.
The novel coronavirus disease 2019 (COVID-19) has reached its pandemic scale within a short period of its first case reported in Wuhan, China in December 2019, leading to a great economic crisis all over the world. As of today, there is no clinically approved antiviral drug available for the treatment of COVID-19. Tocilizumab, a humanized mono- clonal antibody against the interleukin-6 (IL-6) receptor, clinically approved for the treatment of rheumatoid arthritis, is one such drug used to manage the COVID-19 symptoms. The current study reviews the effectiveness of Tocilizum- ab as a treatment option for COVID-19. Research findings on Tocilizumab are effective in COVID-19 patients with the risk of cytokine storm and further complications. Nevertheless, this review also recommends further investigation on the effectiveness of this drug with a large group of patients for more accuracy in results with COVID 19 patients.
Affiliation:
- Universiti Kuala Lumpur - Royal College of Medicine Perak (UniKL-RCMP), 30450 Ipoh, Perak, Malaysia
- Universiti Kuala Lumpur - Royal College of Medicine Perak (UniKL-RCMP), 30450 Ipoh, Perak, Malaysia
- Universiti Kuala Lumpur - Royal College of Medicine Perak (UniKL-RCMP), 30450 Ipoh, Perak, Malaysia
|
|
Indexation |
Indexed by |
MyJurnal (2021) |
H-Index
|
3 |
Immediacy Index
|
0.000 |
Rank |
0 |
Indexed by |
Scopus 2020 |
Impact Factor
|
CiteScore (0.2) |
Rank |
Q4 (Medicine (all)) |
Additional Information |
SJR (0.144) |
|
|
|